FDA approves two combo brand-name AIDS drugs.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D015224:Dideoxynucleosides; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D009943:Organophosphorus Compounds / Q000008:administration & dosage*; D014481:United States; D014486:United States Food and Drug Administration; D000099227:Abacavir
D019380:Anti-HIV Agents; D003841:Deoxycytidine; D015224:Dideoxynucleosides; D004338:Drug Combinations; D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; D019259:Lamivudine; D009943:Organophosphorus Compounds; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir